About this Journal Submit a Manuscript Table of Contents
Case Reports in Hematology
Volume 2012 (2012), Article ID 369086, 4 pages
http://dx.doi.org/10.1155/2012/369086
Case Report

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports

1Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky’ University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech Republic
2First Department of Medicine, Charles University General Hospital, U nemocnice 2, 128 08 Prague, Czech Republic

Received 19 February 2012; Accepted 1 April 2012

Academic Editors: E. Bissé and K. Khair

Copyright © 2012 Peter Rohon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. W. Wijermans, B. Rüter, M. R. Baer, J. L. Slack, H. I. Saba, and M. Lübbert, “Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML),” Leukemia Research, vol. 32, no. 4, pp. 587–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. L. Goddard, A. E. Chesney, M. D. Reis et al., “Pathological splenic rupture: a rare complication of chronic myelomonocytic leukemia,” American Journal of Hematology, vol. 82, no. 5, pp. 405–408, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. S. H. Swerdlow, E. Campo, and N. L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008.
  4. J. Jelinek, Y. Oki, V. Gharibyan et al., “JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia,” Blood, vol. 106, no. 10, pp. 3370–3373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. L. Levine, M. Loriaux, B. J. P. Huntly et al., “The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia,” Blood, vol. 106, no. 10, pp. 3377–3379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Aribi, G. Borthakur, F. Ravandi et al., “Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia,” Cancer, vol. 109, no. 4, pp. 713–717, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Costa, H. Abdulhaq, B. Haq et al., “Activity of azacitidine in chronic myelomonocytic leukemia,” Cancer, vol. 117, no. 12, pp. 2690–2696, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. W. Wijermans, B. Rüter, M. R. Baer, J. L. Slack, H. I. Saba, and M. Lübbert, “Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML),” Leukemia Research, vol. 32, no. 4, pp. 587–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Fabiani, G. Leone, M. Giachelia et al., “Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia,” Leukemia and Lymphoma, vol. 51, no. 12, pp. 2275–2284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Flotho, R. Claus, C. Batz et al., “The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells,” Leukemia, vol. 23, no. 6, pp. 1019–1028, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Weber, I. Hellmann, M. B. Stadler et al., “Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome,” Nature Genetics, vol. 39, no. 4, pp. 457–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Jenuwein and C. D. Allis, “Translating the histone code,” Science, vol. 293, no. 5532, pp. 1074–1080, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Shen, H. Kantarjian, Y. Guo et al., “DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes,” Journal of Clinical Oncology, vol. 28, no. 4, pp. 605–613, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. L. I. Sánchez-Abarca, S. Gutierrez-Cosio, C. Santamaría et al., “Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting,” Blood, vol. 115, no. 1, pp. 107–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Fenaux, G. J. Mufti, E. Hellstrom-Lindberg et al., “Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study,” The Lancet Oncology, vol. 10, no. 3, pp. 223–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Fenaux, D. Bowen, N. Gattermann et al., “Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion,” Leukemia Research, vol. 34, no. 11, pp. 1410–1416, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Itzykson, S. Thépot, B. Quesnel et al., “Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine,” Blood, vol. 117, no. 2, pp. 403–411, 2011. View at Publisher · View at Google Scholar · View at Scopus